Name: UMIN ID:
Unique ID issued by UMIN | UMIN000007004 |
---|---|
Receipt number | R000008190 |
Scientific Title | A phase II study to confirm the effectiveness of a sequence therapy consisted induction therapy (Capecitabin or S-1 or sLV/5-FU plus Bevacizumab) and following therapy (induction therapy + oxaliplatin) for unresectable advanced/recurrent colo-rectal cancer (OGSG 1107) |
Date of disclosure of the study information | 2012/01/04 |
Last modified on | 2022/11/06 10:34:03 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2012/01/03 20:38:12 | ||
2 | Update | 2012/06/24 21:27:21 | Recruitment status |
|
3 | Update | 2012/06/24 21:49:15 | Organization Organization Division name Division name Address Address TEL Name of person sending information Name of person sending information Organization Organization Division name Division name Address Address TEL Organization1 Address1 Tel1 Email1 |
|
4 | Update | 2012/06/24 21:55:41 | Address1 |
|
5 | Update | 2012/07/03 22:39:27 | Acronym Acronym |
|
6 | Update | 2013/04/14 22:36:26 | Public title Public title Acronym Acronym |
|
7 | Update | 2013/04/14 22:51:14 | Narrative objectives1 Narrative objectives1 Primary outcomes Primary outcomes Key secondary outcomes Key secondary outcomes |
|
8 | Update | 2013/04/14 22:53:17 | Anticipated trial start date |
|
9 | Update | 2013/04/15 00:59:55 | Control No. of arms Interventions/Control_1 Interventions/Control_1 Interventions/Control_2 Interventions/Control_2 Interventions/Control_3 Interventions/Control_3 Key exclusion criteria Key exclusion criteria |
|
10 | Update | 2013/07/03 12:16:55 | Last name of lead principal investigator Last name of lead principal investigator |
|
11 | Update | 2015/01/08 00:16:55 | Last name of lead principal investigator Last name of lead principal investigator Last name of contact person Last name of contact person Organization Organization Division name Address Address Institutions |
|
12 | Update | 2015/02/05 22:38:16 | Last follow-up date |
|
13 | Update | 2015/06/10 00:37:19 | Email |
|
14 | Update | 2016/01/04 20:32:41 | Recruitment status Last follow-up date |
|
15 | Update | 2016/07/04 20:40:44 | Name of primary person or sponsor Organization |
|
16 | Update | 2016/07/04 20:48:14 | Control |
|
17 | Update | 2018/04/30 23:44:51 | Email |
|
18 | Update | 2018/05/10 20:31:08 | Email |
|
19 | Update | 2018/08/01 22:00:48 | UMIN ID1 |
|
20 | Update | 2018/08/01 22:03:45 | Name of person sending information Name of person sending information Organization Organization Division name Division name Address Address TEL |
|
21 | Update | 2019/01/08 22:20:56 | Recruitment status Last follow-up date Date analysis concluded |
|
22 | Update | 2020/01/05 18:13:56 | Date of IRB |
|
23 | Update | 2022/11/06 10:34:03 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |